Ancillary molecular testing on fine-needle aspirates can be a valuable tool to determine whether clinical follow-up or surgery is warranted for these patients. Papillary carcinoma, the primary malignancy found in most abnormal thyroid cases, usually carries a BRAF, RET/PTC, or RAS mutation. This evidence concerns the gene RET and papillary carcinoma.